Specific down-regulation of HER-2/neu mediated by a chimeric U6 hammerhead ribozyme results in growth inhibition of human ovarian carcinoma

Vivian W.Y. Lui, Yukai He, Kirti Goyaland, Leaf Huang

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

The U6 expression system was explored for efficient expression of a ribozyme against the human proto-oncogene c-neu. A hammerhead ribozyme (neuRz) and the control mutant ribozyme (MRz) were targeted to cleave c-neu mRNA at the tyrosine kinase domain. In vitro cleavage showed that neuRz was very active while MRz was not. Near-maximal target cleavage observed at a low ribozyme:target ratio (0.1) suggests that neuRz has good activity and turnover capability under physiological conditions, i.e., <5 mM MgCI2 and 37°C. Chimeric U6 ribozyme was expressed at about 5 × 106 copies/cell at 48 h in the ovarian carcinoma cell line SKOV-3.ip1. Partial down-regulation of c-neu mRNA and protein was observed in a dose-dependent manner in cells transiently transfected with U6neuRz- but not with MRz-containing plasmid. Sorted transient transfectants demonstrated dramatic growth inhibition with the neuRz-expressing cells. Our results demonstrate that the U6 expression system is very efficient and suitable for the expression of a hammerhead ribozyme. Moreover, nonviral delivery of the neuRz-expressing plasmid resulted in specific down-regulation of c-neu and, subsequently, growth inhibition of ovarian cancer cells overexpressing c-neu.

Original languageEnglish (US)
Pages (from-to)169-177
Number of pages9
JournalMolecular Therapy
Volume3
Issue number2
DOIs
StatePublished - Jan 1 2001
Externally publishedYes

Fingerprint

Catalytic RNA
Down-Regulation
Carcinoma
Growth
Plasmids
Messenger RNA
Proto-Oncogenes
Ovarian Neoplasms
Protein-Tyrosine Kinases
hammerhead ribozyme
Cell Line
Proteins

Keywords

  • Gene therapy
  • HER-2/neu ribozyme
  • Ovarian cancer growth inhibition
  • U6 RNA

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Cite this

Specific down-regulation of HER-2/neu mediated by a chimeric U6 hammerhead ribozyme results in growth inhibition of human ovarian carcinoma. / Lui, Vivian W.Y.; He, Yukai; Goyaland, Kirti; Huang, Leaf.

In: Molecular Therapy, Vol. 3, No. 2, 01.01.2001, p. 169-177.

Research output: Contribution to journalArticle

@article{5907decde7774e5ead739844f2216d85,
title = "Specific down-regulation of HER-2/neu mediated by a chimeric U6 hammerhead ribozyme results in growth inhibition of human ovarian carcinoma",
abstract = "The U6 expression system was explored for efficient expression of a ribozyme against the human proto-oncogene c-neu. A hammerhead ribozyme (neuRz) and the control mutant ribozyme (MRz) were targeted to cleave c-neu mRNA at the tyrosine kinase domain. In vitro cleavage showed that neuRz was very active while MRz was not. Near-maximal target cleavage observed at a low ribozyme:target ratio (0.1) suggests that neuRz has good activity and turnover capability under physiological conditions, i.e., <5 mM MgCI2 and 37°C. Chimeric U6 ribozyme was expressed at about 5 × 106 copies/cell at 48 h in the ovarian carcinoma cell line SKOV-3.ip1. Partial down-regulation of c-neu mRNA and protein was observed in a dose-dependent manner in cells transiently transfected with U6neuRz- but not with MRz-containing plasmid. Sorted transient transfectants demonstrated dramatic growth inhibition with the neuRz-expressing cells. Our results demonstrate that the U6 expression system is very efficient and suitable for the expression of a hammerhead ribozyme. Moreover, nonviral delivery of the neuRz-expressing plasmid resulted in specific down-regulation of c-neu and, subsequently, growth inhibition of ovarian cancer cells overexpressing c-neu.",
keywords = "Gene therapy, HER-2/neu ribozyme, Ovarian cancer growth inhibition, U6 RNA",
author = "Lui, {Vivian W.Y.} and Yukai He and Kirti Goyaland and Leaf Huang",
year = "2001",
month = "1",
day = "1",
doi = "10.1006/mthe.2000.0241",
language = "English (US)",
volume = "3",
pages = "169--177",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Specific down-regulation of HER-2/neu mediated by a chimeric U6 hammerhead ribozyme results in growth inhibition of human ovarian carcinoma

AU - Lui, Vivian W.Y.

AU - He, Yukai

AU - Goyaland, Kirti

AU - Huang, Leaf

PY - 2001/1/1

Y1 - 2001/1/1

N2 - The U6 expression system was explored for efficient expression of a ribozyme against the human proto-oncogene c-neu. A hammerhead ribozyme (neuRz) and the control mutant ribozyme (MRz) were targeted to cleave c-neu mRNA at the tyrosine kinase domain. In vitro cleavage showed that neuRz was very active while MRz was not. Near-maximal target cleavage observed at a low ribozyme:target ratio (0.1) suggests that neuRz has good activity and turnover capability under physiological conditions, i.e., <5 mM MgCI2 and 37°C. Chimeric U6 ribozyme was expressed at about 5 × 106 copies/cell at 48 h in the ovarian carcinoma cell line SKOV-3.ip1. Partial down-regulation of c-neu mRNA and protein was observed in a dose-dependent manner in cells transiently transfected with U6neuRz- but not with MRz-containing plasmid. Sorted transient transfectants demonstrated dramatic growth inhibition with the neuRz-expressing cells. Our results demonstrate that the U6 expression system is very efficient and suitable for the expression of a hammerhead ribozyme. Moreover, nonviral delivery of the neuRz-expressing plasmid resulted in specific down-regulation of c-neu and, subsequently, growth inhibition of ovarian cancer cells overexpressing c-neu.

AB - The U6 expression system was explored for efficient expression of a ribozyme against the human proto-oncogene c-neu. A hammerhead ribozyme (neuRz) and the control mutant ribozyme (MRz) were targeted to cleave c-neu mRNA at the tyrosine kinase domain. In vitro cleavage showed that neuRz was very active while MRz was not. Near-maximal target cleavage observed at a low ribozyme:target ratio (0.1) suggests that neuRz has good activity and turnover capability under physiological conditions, i.e., <5 mM MgCI2 and 37°C. Chimeric U6 ribozyme was expressed at about 5 × 106 copies/cell at 48 h in the ovarian carcinoma cell line SKOV-3.ip1. Partial down-regulation of c-neu mRNA and protein was observed in a dose-dependent manner in cells transiently transfected with U6neuRz- but not with MRz-containing plasmid. Sorted transient transfectants demonstrated dramatic growth inhibition with the neuRz-expressing cells. Our results demonstrate that the U6 expression system is very efficient and suitable for the expression of a hammerhead ribozyme. Moreover, nonviral delivery of the neuRz-expressing plasmid resulted in specific down-regulation of c-neu and, subsequently, growth inhibition of ovarian cancer cells overexpressing c-neu.

KW - Gene therapy

KW - HER-2/neu ribozyme

KW - Ovarian cancer growth inhibition

KW - U6 RNA

UR - http://www.scopus.com/inward/record.url?scp=0034986068&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034986068&partnerID=8YFLogxK

U2 - 10.1006/mthe.2000.0241

DO - 10.1006/mthe.2000.0241

M3 - Article

VL - 3

SP - 169

EP - 177

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 2

ER -